Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details.
- Share Price: 1376.03 pence per Share.
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Dividend Payment Date: January 14, 2016.
Material Changes
The filing reports specific share acquisitions by the following individuals following the dividend re-investment:
- Sir Andrew Witty (Director): Acquired 7,154 Ordinary Shares.
- Lady C Witty (Connected Person of Sir Andrew Witty): Acquired 2,241 Ordinary Shares.
- Mr I W Whyte (Connected Person of Mrs V A Whyte): Acquired 397 Ordinary Shares.
No other material changes to the company's financial position or operations are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of insider trading activity rather than a financial performance report.
Investor Verification Checklist
- Verify the total number of shares held by Sir Andrew Witty and connected persons post-transaction.
- Confirm the dividend per share amount implied by the re-investment price of 1376.03 pence.
- Check subsequent filings for any changes in director shareholdings or additional connected person transactions.